Buscar
Mostrando ítems 1-10 de 20
Cholinesterase inhibitors for Alzheimer's disease: Multitargeting strategy based on anti-Alzheimer's drugs repositioning
(Bentham Science Publishers, 2019)
Efeito da hesperidina sobre o déficit cognitivo e o sistema colinérgico de ratos submetidos a um modelo de demência esporádica do tipo alzheimer
(Universidade Federal de Santa MariaBrasilBioquímicaUFSMPrograma de Pós-Graduação em Ciências Biológicas: Bioquímica ToxicológicaCentro de Ciências Naturais e Exatas, 2017-10-16)
Alzheimer's disease (AD) is considered the main cause of dementia in the world and the search for new therapeutic interventions for its treatment is of great relevance. Preclinical studies suggest the use of hesperidin ...
Benzodiazepines and Related Drugs as a Risk Factor in Alzheimer's Disease Dementia
(Frontiers Media S.A., 2020)
Design, Synthesis, Biological Evaluation and Molecular Modelling of Substituted pyrrolo[2,1-a]isoquinolinone derivatives: Discovery of Potent Inhibitors of AChE and BChE
(Royal Society of Chemistry, 2021-04)
We report here the design, synthesis and biological evaluation of a new series of substituted pyrrolo[2,1-a]isoquinolin-3-one derivatives, some of which have strong inhibitory activity against both AChE and BChE enzymes. ...
Determinación en membranas celulares y modelos moleculares del efecto protector de drogas utilizadas en la enfermedad de Alzheimer.Determination in cell membranes and molecular models of the protective effect of drugs used in Alzheimer's disease.
(2019)
El péptido beta amiloide (Aβ) es tóxico para las neuronas. Desde hace más de una década se han examinado los efectos de medicamentos que tienen una acción inhibidora de la acetilcolinesterasa, con lo cual se han mejorado ...
Arylaminopropanone Derivatives as Potential Cholinesterase Inhibitors: Synthesis, Docking Study and Biological Evaluation
(Molecular Diversity Preservation International, 2020-04)
Neurodegenerative diseases in which the decrease of the acetylcholine is observed are growing worldwide. In the present study, a series of new arylaminopropanone derivatives with N-phenylcarbamate moiety (1-16) were prepared ...
Pharmacotherapies for Parkinson’s disease symptoms related to cholinergic degeneration
(Informa Healthcare, 2016-10)
Introduction: Dopamine depletion is one of the most important features of Parkinson’s Disease (PD). However, insufficient response to dopaminergic replacement therapy suggests the involvement of other neurotransmitter ...
Identifying and responding to fatigue and apathy in Parkinson’s disease: a review of current practice
(Taylor & Francis, 2020)
Introduction: Fatigue and apathy are two key non-motor symptoms in Parkinson's disease (PD), with documented negative impact on Quality of life (QoL) and a frequent burden for caregivers. Areas covered: In this review, the ...
Pharmacotherapies for parkinson's disease symptoms related to cholinergic degeneration
(Taylor & Francis, 2022)